Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500)

American Journal of Hematology

Volumn 82, Issue 12, 2007, Pages 1056-1062

  Petersdorf, Stephen H ^a,i   Rankin, Cathryn ^b   Head, David R ^c   Terebelo, Howard R ^d   Willman, Cheryl L ^e   Balcerzak, Stanley P ^f   Karnad, Anand B ^g   Dakhil, Shaker R ^h   Appelbaum, Frederick R ^a  

^a SEATTLE CANCER CARE ALLIANCE   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d Newland Medical Associates   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

ⁱ Medical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOPENIA; DEMOGRAPHY; DIARRHEA; DRUG MEGADOSE; DYSPNEA; FATIGUE; FEMALE; FEVER; HEART ARRHYTHMIA; HUMAN; HYPERBILIRUBINEMIA; INFECTION; KIDNEY FAILURE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; NYSTAGMUS; OVERALL SURVIVAL; PAIN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT INFECTION; SPEECH DISORDER; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL; TYPHLITIS; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; ETHNIC GROUPS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 36749029331     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20994     Document Type: Article

References (25)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia (Review). N Engl J Med 1999;341:1051-1062.
2. Appelbaum FR, Rowe MJ, Radich J, Dick JE. Acute myeloid leukemia. In: Schlechter GP, Broudy VC, Williams ME, editors. Hematology 2001: The American Society of Hematology Education Program Book. Washington, DC: The American Society of Hematology; 2001. pp 62-86.
3. Stone RM. Treatment of acute myeloid leukemia: State-of-the-art and future directions (Review). Semin Hematol 2002;39:4-10.
4. Zittoun RA, Mandelli F, Willemze R, de Witte T Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995;332:217-223.
5. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000;96:4075-4083.
6. Estey EH. Therapeutic options for acute myelogenous leukemia (Review). Cancer 2001;92:1059-1073.
7. Lowenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology 2003;82-101.
8. Bolwell BJ, Cassileth PA, Gale RP. High dose cytarabine: A review (Review). Leukemia 1988;2:253-260.
9. Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GR High-dose cytosine arabinoside therapy with and without anthracycllne antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 1985;3:992-997.
10. Karanes C, Kopecky KJ, Grever MR, Hynes HE, Kraut EH, Vial RH, et al. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia. Southwest Oncology Group Study. Leuk Res 1999;23:787-794.
11. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study. Blood 1996;88:2841-2851.
12. Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, et al. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 1995;13:560-569.
13. Cassileth PA, Andersen J, Lazarus HM, Colvin OM, Bennett JM, Stadtmauer EA, et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 1993;11:314-319.
14. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, et al. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992;80:2977-2982.
15. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896-903.
16. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-819.
17. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77:1666-1674.
18. Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, Todd MB, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79:313-319.
19. Bishop JF, Matthews JP, Young GA, Bradstock K, Lowenthal RM. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: A review and updated results of the Australian Leukemia Study Group (Review). Leuk Lymphoma 1998;28:315-327.
20. Stein AS, O'Donnell MR, Slovak ML, Nademanee A, Dagis A, Schmidt GM, et al. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: Impact of cytogenetics on achieving a complete remission. Leukemia 2000;14:1191-1196.
21. Cassileth PA, Lee SJ, Litzow MR, Miller KB, Stadtmauer EA, Tallman MS, et al. Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: An Eastern Cooperative Oncology Group trial (E4995). Leuk Lymphoma 2005;46:55-61.
22. Bradstock KF, Matthews JR Lowenthal RM, Baxter H, Catalano J, Brighton T, et al. A ransomized trial of high-versus conventional-dose chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005;105:481-488.
23. Kern W, Estey E. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia. Cancer 2006;107:116-24.
24. Appelbaum FR, Kopecky KJ. Long-term survival after chemotherapy for acute myeloid leukemia: The experience of the Southwest Oncology Group. Cancer 1997;80:2199-2204.
25. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukemia Working Parties. Blood 1998;92:2322-2333.